[go: up one dir, main page]

WO2003077796A3 - Ophthalmic solutions for delivery of expression vectors - Google Patents

Ophthalmic solutions for delivery of expression vectors Download PDF

Info

Publication number
WO2003077796A3
WO2003077796A3 PCT/US2003/007918 US0307918W WO03077796A3 WO 2003077796 A3 WO2003077796 A3 WO 2003077796A3 US 0307918 W US0307918 W US 0307918W WO 03077796 A3 WO03077796 A3 WO 03077796A3
Authority
WO
WIPO (PCT)
Prior art keywords
vector
expression
tears
composition
expression vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/007918
Other languages
French (fr)
Other versions
WO2003077796A2 (en
Inventor
Erlinda M Gordon
Frederick L Hall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Priority to AU2003218168A priority Critical patent/AU2003218168A1/en
Publication of WO2003077796A2 publication Critical patent/WO2003077796A2/en
Publication of WO2003077796A3 publication Critical patent/WO2003077796A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention provides improved ophthalmic solutions useful for storing and/or delivering expression vectors. More specifically, this invention provides a stable aqueous ophthalmic composition comprising an expression vector and a vector stabilizing agent such as serum albumin, sucrose, or lactose. The stabilizing agent is in an amount that maintains the potency (i.e., expression efficiency) of the vector. This invention further provides method of ameliorating ocular diseases or conditions in a mammal using the same opthalmic composition, wherein the vector expresses a protein useful in the treatment of the ocular diseases or conditions. The ophtalmic composition can be administrated topically or systematically. Fig. 1 compares the expression efficiencies of a dnG1 vector in an ophthalmic solution of this invention (A), Genteal Lubricant Eye Drops (B), Three Tears (C), Refresh Tears (D), or Visine Tears (E) using viral titers.
PCT/US2003/007918 2002-03-15 2003-03-14 Ophthalmic solutions for delivery of expression vectors Ceased WO2003077796A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003218168A AU2003218168A1 (en) 2002-03-15 2003-03-14 Ophthalmic solutions for delivery of expression vectors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36478702P 2002-03-15 2002-03-15
US60/364,787 2002-03-15

Publications (2)

Publication Number Publication Date
WO2003077796A2 WO2003077796A2 (en) 2003-09-25
WO2003077796A3 true WO2003077796A3 (en) 2004-05-21

Family

ID=28041960

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/007918 Ceased WO2003077796A2 (en) 2002-03-15 2003-03-14 Ophthalmic solutions for delivery of expression vectors

Country Status (2)

Country Link
AU (1) AU2003218168A1 (en)
WO (1) WO2003077796A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637534B2 (en) 2013-03-13 2017-05-02 Genzyme Corporation Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007261315B2 (en) 2006-06-21 2012-10-25 Musc Foundation For Research Development Targeting complement factor H for treatment of diseases
US9132193B2 (en) * 2012-11-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Use of Slurp1 as an imunomodulatory molecule in the ocular surface
WO2017070491A1 (en) * 2015-10-23 2017-04-27 Applied Genetic Technologies Corporation Ophthalmic formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040839A1 (en) * 1996-04-26 1997-11-06 Merck & Co., Inc. Dna vaccine formulations
WO1999045966A1 (en) * 1998-03-13 1999-09-16 American Home Products Corporation Polynucleotide composition, method of preparation, and use thereof
US6204251B1 (en) * 1994-10-31 2001-03-20 Genentech, Inc. Ocular gene therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204251B1 (en) * 1994-10-31 2001-03-20 Genentech, Inc. Ocular gene therapy
WO1997040839A1 (en) * 1996-04-26 1997-11-06 Merck & Co., Inc. Dna vaccine formulations
WO1999045966A1 (en) * 1998-03-13 1999-09-16 American Home Products Corporation Polynucleotide composition, method of preparation, and use thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637534B2 (en) 2013-03-13 2017-05-02 Genzyme Corporation Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof
US10183983B2 (en) 2013-03-13 2019-01-22 Genzyme Corporation Nucleic acids encoding fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof
US11084864B2 (en) 2013-03-13 2021-08-10 Genzyme Corporation Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof

Also Published As

Publication number Publication date
WO2003077796A2 (en) 2003-09-25
AU2003218168A8 (en) 2003-09-29
AU2003218168A1 (en) 2003-09-29

Similar Documents

Publication Publication Date Title
Peplinski et al. Deepening of lid sulcus from topical bimatoprost therapy
JP2023085558A5 (en)
BR9808016A (en) Compositions and methods for reducing ocular hypertension
USD466610S1 (en) Eye patch for treatment of amblyopia
TW200420275A (en) Devices and methods for improving vision
CA2507375A1 (en) Use of rimexolone in the treatment of dry eye
AU2003274734A1 (en) Method and composition containing latanoprost for treating ocular hypertension and glaucoma
ATE147619T1 (en) OPTHALMIC COMPOSITIONS CONTAINING A CYCLOSPORIN
WO2003092665A3 (en) Ocular drug delivery systems and use thereof
WO2002013863A2 (en) Presbyopia treatment by lens alteration
TWM378730U (en) Fixation structure improvement of secondary glasses frame
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
WO2003077796A3 (en) Ophthalmic solutions for delivery of expression vectors
EP1050308A4 (en) Preventives or remedies for vision disorders
WO2000056273A3 (en) Non-irritating cleansing composition
WO2002049611A3 (en) Ophthalmic lubricating solution adapted for use in lasik surgery
CA2282757A1 (en) Opthalmic composition
NZ602479A (en) Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion
US8207129B2 (en) Treatment with cyclosporin A
WO2003061519A3 (en) Methods and compositions for preserving the viability of photoreceptor cells
WO2002065943A3 (en) Ocular tear growth factor-like protein
AU2002329042A1 (en) Ophthalmic composition containing n-acetylcysteine for the treat ment of dry-eye syndrome
JPH0854583A (en) Coupling structure of nose pad and pad box
WO1995009611A3 (en) Stable protein: phospholipid compositions and methods
MXPA03010363A (en) Method for treating ocular hypertension and glaucoma.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP